Skip to content
Tasquinimod
Tasquinimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target histone deacetylase 4.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61221——5
Castration-resistant prostatic neoplasmsD064129—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Hepatocellular carcinomaD006528C22.0—1———1
Stomach neoplasmsD013274EFO_0003897C16—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.01————1
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTASQUINIMOD
INNtasquinimod
Description
Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes.
Classification
Small molecule
Drug classimmunomodulators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C
Identifiers
PDB—
CAS-ID254964-60-8
RxCUI—
ChEMBL IDCHEMBL2107784
ChEBI ID—
PubChem CID54682876
DrugBankDB05861
UNII ID756U07KN1R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HDAC4
HDAC4
Organism
Homo sapiens
Gene name
HDAC4
Gene synonyms
KIAA0288
NCBI Gene ID
9759
Protein name
histone deacetylase 4
Protein synonyms
histone deacetylase A
Uniprot ID
Q9UND6
Mouse ortholog
Hdac4 (208727)
histone deacetylase 4 (Q6NZM9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 394 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details